Arobella Medical, LLC, Minneapolis, MN, has launched the Qoustic Wound Therapy System, which advances the use of low-frequency cavitational ultrasound for wound care. The product offers a safe, cost-effective alternative to painful sharps debridement and other surgical modalities, according to the manufacturer. The portable Qoustic Wound Therapy System assists healing by gently removing dead or diseased tissue cells and bacteria, leaving healthy and prehealing granulation tissue intact. It is also useful in preparing the wound bed for other therapies, such as grafts and flaps, according to the manufacturer.
Organogenesis, Inc, Canton, MA, has launched a direct-to-consumer educational campaign for a living cell-based therapy. As the first Food and Drug Administration-approved bioengineered living cell therapy, Apligraf has been used successfully to treat patients worldwide with diabetic foot and venous leg ulcers, according to the manufacturer. The campaign will highlight the medical advances that resulted in bioactive wound products, such as Apligraf, which is designed to assist the body's natural healing process in hard-to-heal wounds.
PolyRemedy, Inc, Mountain View, CA, manufacturer of a robotic system for the delivery of nanomaterial-based wound dressings at the point-of-care, announced it closed a $25 million investment from leading venture capital firms. The Series B financing was co-led by Advanced Technology Ventures and IDG Ventures Boston and included participation from Series A investor, MedVenture Associates, and new investor, Harris & Harris Group, Inc, New York, NY.
The PolyRemedy system enables clinicians to quickly and cost-effectively provide custom-made, unit-of-use wound dressings to patients with chronic wounds, such as diabetic ulcers, and will enable the capture and monitoring of patient data to refine clinical protocols, control costs, and demonstrate evidence-based improvements in wound heal rates over time, according to the manufacturer.
ULURU Inc, Addison, TX, plans to debut its first wound care product, Altrazeal, in the second quarter of 2008. As part of its launch process, the company is conducting numerous market research surveys. Results of the first study-targeting burn specialists, emergency department and trauma physicians, wound care clinic physicians, and nurses from these specialty areas-indicated that the product concept is favorably received, according to the manufacturer. Positive feedback related to the product's ease of use, less frequent dressing changes, no need for a secondary dressing, and the ability of Altrazeal to seal and conform to the wound.